Comparative Effectiveness of Venetoclax Combinations Vs Other Therapies Among Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from the AML Real World Evidence (ARC) Initiative

Introduction: Venetoclax (VEN) is a BCL-2 inhibitor FDA approved in combination with azacitidine (AZA), decitabine (DEC), or low-dose cytarabine (LDAC) for newly diagnosed (ND) acute myeloid leukemia (AML) in adults aged ≥75 or those with comorbidities precluding intensive chemotherapy. We explored...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2021-11, Vol.138 (Supplement 1), p.2328-2328
Hauptverfasser:	Garcia, Jacqueline S., Wolach, Ofir, Vachhani, Pankit, Zeidner, Joshua F., Talati, Chetasi, Pollyea, Daniel A., Lai, Catherine, Moshe, Yakir, Abedin, Sameem, Lavie, David, Zuckerman, Tsila, Xavier, Marin, Lee, Sangmin, Edwards, Wesleigh, Chen, Evan, Bui, Cat N., Svensson, Anders, Burne, Rebecca, Kye, Steve, Maitland, Jessica, Ma, Esprit, Montez, Melissa, Grunspan, Moshe, Goldberg, Aaron D
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!